{"id":"nalmefene","rwe":[],"_fda":{"id":"52b8bd13-33cb-4def-a172-8853a39fe4c4","set_id":"22d67228-6c24-47ca-afc7-52ef279520a0","openfda":{"upc":["6950425900789"],"unii":["K7K69QC05X"],"route":["INTRAMUSCULAR","INTRAVENOUS","SUBCUTANEOUS"],"rxcui":["2592953","2672926"],"spl_id":["52b8bd13-33cb-4def-a172-8853a39fe4c4"],"brand_name":["nalmefene hydrochloride"],"spl_set_id":["22d67228-6c24-47ca-afc7-52ef279520a0"],"package_ndc":["82432-101-01","82432-102-02"],"product_ndc":["82432-101","82432-102"],"generic_name":["NALMEFENE HYDROCHLORIDE INJECTION"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["NALMEFENE HYDROCHLORIDE"],"manufacturer_name":["Chengdu Shuode Pharmaceutical Co., Ltd"],"application_number":["ANDA216007"],"is_original_packager":[true]},"version":"5","warnings":["WARNINGS Use of Nalmefene Hydrochloride Injection in Emergencies Nalmefene Hydrochloride Injection, like all drugs in this class, is not the primary treatment for ventilatory failure. In most emergency settings, treatment with Nalmefene Hydrochloride Injection should follow, not precede, the establishment of a patent airway, ventilatory assistance, administration of oxygen, and establishment of circulatory access. Risk of Recurrent Respiratory Depression Accidental overdose with long acting opioids [such as methadone and levo -alpha- acetylmethadol (LAAM)] may result in prolonged respiratory depression. Respiratory depression in both the postoperative and overdose setting may be complex and involve the effects of anesthetic agents, neuromuscular blockers, and other drugs. While nalmefene hydrochloride injection has a longer duration of action than naloxone in fully reversing doses, the physician should be aware that a recurrence of respiratory depression is possible, even after an apparently adequate initial response to nalmefene hydrochloride injection treatment. Patients treated with Nalmefene Hydrochloride Injection should be observed until, in the opinion of the physician, there is no reasonable risk of recurrent respiratory depression."],"overdosage":["OVERDOSAGE Intravenous doses of up to 24 mg of nalmefene, administered to healthy volunteers in the absence of opioid agonists, produced no serious adverse reactions, severe signs or symptoms, or clinically significant laboratory abnormalities. As with all opioid antagonists, use in patients physically dependent on opioids can result in precipitated withdrawal reactions that may result in symptoms that require medical attention. Treatment of such cases should be symptomatic and supportive. Administration of large amounts of opioids to patients receiving opioid antagonists in an attempt to overcome a full blockade has resulted in adverse respiratory and circulatory reactions."],"description":["Nalmefene Hydrochloride Injection Rx only DESCRIPTION Nalmefene Hydrochloride Injection, an opioid antagonist, is a 6-methylene analogue of naltrexone. The chemical structure is shown below: Molecular Formula: C 21 H 25 NO 3 •HCl•H 2 O Molecular Weight: 393.91, CAS # 1228646-72-7 Chemical Name: 17-(Cyclopropylmethyl)-4,5α-epoxy-6-methylenemorphinan-3,14-diol, hydrochloride salt, monohydrate Nalmefene hydrochloride is a white to almost white crystalline powder which is freely soluble in water up to 130 mg/mL and slightly soluble in chloroform up to 0.13 mg/mL, with a pK a of 7.6. Nalmefene Hydrochloride Injection is available as a sterile solution for intravenous, intramuscular, and subcutaneous administration in two concentrations, containing 100 µg or 1.0 mg of nalmefene free base per mL. The 100 µg/mL concentration contains 110.8 µg of nalmefene hydrochloride and the 1.0 mg/mL concentration contains 1.108 mg of nalmefene hydrochloride per mL. Both concentrations contain 9.0 mg of sodium chloride per mL and the pH is adjusted in the range of 3.3-3.5 with hydrochloric acid. Concentrations and dosages of Nalmefene Hydrochloride Injection are expressed as the free base equivalent of nalmefene. image description"],"precautions":["PRECAUTIONS General CARDIOVASCULAR RISKS WITH NARCOTIC ANTAGONISTS Pulmonary edema, cardiovascular instability, hypotension, hypertension, ventricular tachycardia, and ventricular fibrillation have been reported in connection with opioid reversal in both postoperative and emergency department settings. In many cases, these effects appear to be the result of abrupt reversal of opioid effects. Although nalmefene hydrochloride injection has been used safely in patients with pre-existing cardiac disease, all drugs of this class should be used with caution in patients at high cardiovascular risk or who have received potentially cardiotoxic drugs. (See DOSAGE AND ADMINISTRATION .) RISK OF PRECIPITATED WITHDRAWAL Nalmefene hydrochloride injection, like other opioid antagonists, is known to produce acute withdrawal symptoms and, therefore, should be used with extreme caution in patients with known physical dependence on opioids or following surgery involving high doses of opioids. Imprudent use or excessive doses of opioid antagonists in the postoperative setting has been associated with hypertension, tachycardia, and excessive mortality in patients at high risk for cardiovascular complications. (See PRECAUTIONS .) INCOMPLETE REVERSAL OF BUPRENORPHINE Preclinical studies have shown that nalmefene at doses up to 10 mg/kg (437 times the maximum recommended human dose) produced incomplete reversal of buprenorphine- induced analgesia in animal models. This appears to be a consequence of a high affinity and slow displacement of buprenorphine from the opioid receptors. Hence, nalmefene hydrochloride injection may not completely reverse buprenorphine-induced respiratory depression. Drug Interactions Nalmefene hydrochloride injection has been administered after benzodiazepines, inhalational anesthetics, muscle relaxants, and muscle relaxant antagonists administered in conjunction with general anesthesia. It also has been administered in outpatient settings, both in trials in conscious sedation and in the emergency management of overdose following a wide variety of agents. No deleterious interactions have been observed. Preclinical studies have shown that both flumazenil and nalmefene can induce seizures in animals. The coadministration of both flumazenil and nalmefene produced fewer seizures than expected in a study in rodents, based on the expected effects of each drug alone. Based on these data, an adverse interaction from the coadministration of the two drugs is not expected, but physicians should remain aware of the potential risk of seizures from agents in these classes. Carcinogenesis, Mutagenesis, Impairment of Fertility Nalmefene did not have mutagenic activity in the Ames test with five bacterial strains or the mouse lymphoma assay. Clastogenic activity was not observed in the mouse micronucleus test or in the cytogenic bone marrow assay in rats. However, nalmefene did exhibit a weak but significant clastogenic activity in the human lymphocyte metaphase assay in the absence but not in the presence of exogenous metabolic activation. Oral administration of nalmefene up to 1200 mg/m 2 /day did not affect fertility, reproductive performance, and offspring survival in rats. Use in Pregnancy Reproduction studies have been performed in rats (up to 1200 mg/m 2 /day) and rabbits (up to 2400 mg/m 2 /day) by oral administration of nalmefene and in rabbits by intravenous administration up to 96 mg/m 2 /day (114 times the human dose). There was no evidence of impaired fertility or harm to the fetus. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. Nursing Mothers Nalmefene and its metabolites were secreted into rat milk, reaching concentrations approximately three times those in plasma at one hour and decreasing to about half the corresponding plasma concentrations by 24 hours following bolus administration. As no clinical information is available, caution should be exercised when Nalmefene Hydrochloride Injection is administered to a nursing woman. Use in Pediatric Patients Safety and effectiveness of nalmefene hydrochloride injection in pediatric patients have not been established. Use in Neonates The safety and effectiveness of nalmefene hydrochloride injection in neonates have not been established in clinical studies. In a preclinical study, nalmefene was administered by subcutaneous injection to rat pups at doses up to 205 mg/m 2 /day throughout maternal lactation without producing adverse effects. A preclinical study evaluating the irritancy of the dosage form following arterial and venous administration in animals showed no vascular irritancy. Nalmefene Hydrochloride Injection should only be used in the resuscitation of the newborn when, in the opinion of the treating physician, the expected benefits outweigh the risks. Geriatric Use Clinical studies of nalmefene hydrochloride injection did not include sufficient number of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy."],"how_supplied":["HOW SUPPLIED Nalmefene Hydrochloride Injection is available in the following presentations: A single-dose vial containing 1 mL of 100 µg/mL nalmefene base (Blue Label) Box of 1 (NDC 82432-101-01) A single-dose vial containing 2 mL of 1 mg/mL nalmefene base (Green Label) Box of 1 (NDC 82432-102-02) Protect from light, store at 20°C-25°C (68°F to 77°F). [see USP Controlled Room Temperature] Discard unused portion. Manufacturer Chengdu Shuode Pharmaceutical Co., Ltd No. 9 Lekang Road, Shuangliu District Chengdu, Sichuan 610200 China (CHN) Revision date: 06/27/2023"],"effective_time":"20231208","pharmacodynamics":["Pharmacodynamics Nalmefene hydrochloride injection prevents or reverses the effects of opioids, including respiratory depression, sedation, and hypotension. Pharmacodynamic studies have shown that nalmefene hydrochloride injection has a longer duration of action than naloxone at fully reversing doses. Nalmefene hydrochloride injection has no opioid agonist activity. Nalmefene hydrochloride injection is not known to produce respiratory depression, psychotomimetic effects, or pupillary constriction. No pharmacological activity was observed when nalmefene hydrochloride injection was administered in the absence of opioid agonists. Nalmefene hydrochloride injection has not been shown to produce tolerance, physical dependence, or abuse potential. Nalmefene hydrochloride injection can produce acute withdrawal symptoms in individuals who are opioid dependent."],"pharmacokinetics":["Pharmacokinetics Nalmefene exhibited dose proportional pharmacokinetics following intravenous administration of 0.5 mg to 2.0 mg. Pharmacokinetic parameters for nalmefene after a 1 mg intravenous administration in adult male volunteers are listed in Table 1. Table 1: Mean (CV%) Nalmefene Pharmacokinetic Parameters InAdult Males Following a 1 mg Intravenous Dose Parameter Young, N=18 Elderly, N=11 Age 19-32 62-80 Cp at 5 min. (ng/mL) 3.7 (29) 5.8 (38) Vdss (L/kg) 8.6 (19) 8.6 (29) Vc (L/kg) 3.9 (29) 2.8 (41) AUC0-inf (ng-hr/mL) 16.6 (27) 17.3 (14) Terminal T1/2 (hr) 10.8 (48) 9.4 (49) Clplasma (L/hr/kg) 0.8 (23) 0.8 (18) ABSORPTION Nalmefene was completely bioavailable following intramuscular or subcutaneous administration in 12 male volunteers relative to intravenous nalmefene. The relative bioavailabilities of intramuscular and subcutaneous routes of administration were 101.5% ± 8.1% (Mean ± SD) and 99.7% ± 6.9%, respectively. Nalmefene will be administered primarily as an intravenous bolus, however, nalmefene can be given intra-muscularly (IM) or subcutaneously (SC) if venous access cannot be established. While the time to maximum plasma nalmefene concentration was 2.3 ± 1.1 hours following intramuscular and 1.5 ± 1.2 hours following subcutaneous administrations, therapeutic plasma concentrations are likely to be reached within 5-15 minutes after a 1 mg dose in an emergency. Because of the variability in the speed of absorption for IM & SC dosing, and the inability to titrate to effect, great care should be taken if repeated doses must be given by these routes. DISTRIBUTION Following a 1 mg parenteral dose, nalmefene was rapidly distributed. In a study of brain receptor occupancy, a 1 mg dose of nalmefene blocked over 80% of brain opioid receptors within 5 minutes after administration. The apparent volumes of distribution centrally (Vc) and at steady-state (Vdss) are 3.9 ± 1.1 L/kg and 8.6 ± 1.7 L/kg, respectively. Ultrafiltration studies of nalmefene have demonstrated that 45% (CV 4.1%) is bound to plasma proteins over a concentration range of 0.1 to 2 µg/mL. An in vitro determination of the distribution of nalmefene in human blood demonstrated that nalmefene distributed 67% (CV 8.7%) into red blood cells and 39% (CV 6.4%) into plasma. The whole blood to plasma ratio was 1.3 (CV 6.6%) over the nominal concentration range in whole blood from 0.376 to 30 ng/mL. METABOLISM Nalmefene is metabolized by the liver, primarily by glucuronide conjugation, and excreted in the urine. Nalmefene is also metabolized to trace amounts of an N- dealkylated metabolite. Nalmefene glucuronide is inactive and the N-dealkylated metabolite has minimal pharmacological activity. Less than 5% of nalmefene is excreted in the urine unchanged. Seventeen percent (17%) of the nalmefene dose is excreted in the feces. The plasma concentration-time profile in some subjects suggests that nalmefene undergoes enterohepatic recycling. ELIMINATION After intravenous administration of 1 mg nalmefene hydrochloride injection to normal males (ages 19-32), plasma concentrations declined biexponentially with a redistribution and a terminal elimination half-life of 41 ± 34 minutes and 10.8 ± 5.2 hours, respectively. The systemic clearance of nalmefene is 0.8 ± 0.2 L/hr/kg and the renal clearance is 0.08 ± 0.04 L/hr/kg."],"adverse_reactions":["ADVERSE REACTIONS Adverse event information was obtained following administration of nalmefene hydrochloride injection to 152 normal volunteers and in controlled clinical trials to 1127 patients for the treatment of opioid overdose or for postoperative opioid reversal. Nalmefene was well tolerated and showed no serious toxicity during experimental administration to healthy individuals, even when given at 15 times the highest recommended dose. In a small number of subjects, at doses exceeding the recommended nalmefene hydrochloride injection dose, nalmefene produced symptoms suggestive of reversal of endogenous opioids, such as have been reported for other narcotic antagonist drugs. These symptoms (nausea, chills, myalgia, dysphoria, abdominal cramps, and joint pain) were usually transient and occurred at very low frequency. Such symptoms of precipitated opioid withdrawal at the recommended clinical doses were seen in both postoperative and overdose patients who were later found to have had histories of covert opioid use. Symptoms of precipitated withdrawal were similar to those seen with other opioid antagonists, were transient following the lower doses used in the postoperative setting, and more prolonged following the administration of the larger doses used in the treatment of overdose. Tachycardia and nausea following the use of nalmefene in the postoperative setting were reported at the same frequencies as for naloxone at equivalent doses. The risk of both these adverse events was low at doses giving partial opioid reversal and increased with increases in dose. Thus, total doses larger than 1.0 µg/kg in the postoperative setting and 1.5 mg/70 kg in the treatment of overdose are not recommended. Relative Frequencies of Common Adverse Reactions With an Incidence Greater than 1% (all patients, all clinical settings) Adverse Event Nalmefene Naloxone Placebo N=1127 N=369 N=77 Nausea 18% 18% 6% Vomiting 9% 7% 4% Tachycardia 5% 8% - Hypertension 5% 7% - Postoperative pain 4% 4% N/A Fever 3% 4% - Dizziness 3% 4% 1% Headache 1% 1% 4% Chills 1% 1% - Hypotension 1% 1% - Vasodilatation 1% 1% - Incidence less than 1% CARDIOVASCULAR: Bradycardia, arrhythmia DIGESTIVE: Diarrhea, dry mouth NERVOUS SYSTEM: Somnolence, depression, agitation, nervousness, tremor, confusion, withdrawal syndrome, myoclonus RESPIRATORY: Pharyngitis SKIN: Pruritus UROGENITAL: Urinary retention The incidence of adverse events was highest in patients who received more than the recommended dose of nalmefene hydrochloride injection. Laboratory findings: Transient increases in CPK were reported as adverse events in 0.5% of the postoperative patients studied. These increases were believed to be related to surgery and not believed to be related to the administration of nalmefene hydrochloride injection. Increases in AST were reported as adverse events in 0.3% of the patients receiving either nalmefene or naloxone. The clinical significance of this finding is unknown. No cases of hepatitis or hepatic injury due to either nalmefene or naloxone were observed in the clinical trials."],"contraindications":["CONTRAINDICATIONS Nalmefene Hydrochloride Injection is contraindicated in patients with a known hypersensitivity to the product."],"clinical_pharmacology":["CLINICAL PHARMACOLOGY Pharmacodynamics Nalmefene hydrochloride injection prevents or reverses the effects of opioids, including respiratory depression, sedation, and hypotension. Pharmacodynamic studies have shown that nalmefene hydrochloride injection has a longer duration of action than naloxone at fully reversing doses. Nalmefene hydrochloride injection has no opioid agonist activity. Nalmefene hydrochloride injection is not known to produce respiratory depression, psychotomimetic effects, or pupillary constriction. No pharmacological activity was observed when nalmefene hydrochloride injection was administered in the absence of opioid agonists. Nalmefene hydrochloride injection has not been shown to produce tolerance, physical dependence, or abuse potential. Nalmefene hydrochloride injection can produce acute withdrawal symptoms in individuals who are opioid dependent. Pharmacokinetics Nalmefene exhibited dose proportional pharmacokinetics following intravenous administration of 0.5 mg to 2.0 mg. Pharmacokinetic parameters for nalmefene after a 1 mg intravenous administration in adult male volunteers are listed in Table 1. Table 1: Mean (CV%) Nalmefene Pharmacokinetic Parameters InAdult Males Following a 1 mg Intravenous Dose Parameter Young, N=18 Elderly, N=11 Age 19-32 62-80 Cp at 5 min. (ng/mL) 3.7 (29) 5.8 (38) Vdss (L/kg) 8.6 (19) 8.6 (29) Vc (L/kg) 3.9 (29) 2.8 (41) AUC0-inf (ng-hr/mL) 16.6 (27) 17.3 (14) Terminal T1/2 (hr) 10.8 (48) 9.4 (49) Clplasma (L/hr/kg) 0.8 (23) 0.8 (18) ABSORPTION Nalmefene was completely bioavailable following intramuscular or subcutaneous administration in 12 male volunteers relative to intravenous nalmefene. The relative bioavailabilities of intramuscular and subcutaneous routes of administration were 101.5% ± 8.1% (Mean ± SD) and 99.7% ± 6.9%, respectively. Nalmefene will be administered primarily as an intravenous bolus, however, nalmefene can be given intra-muscularly (IM) or subcutaneously (SC) if venous access cannot be established. While the time to maximum plasma nalmefene concentration was 2.3 ± 1.1 hours following intramuscular and 1.5 ± 1.2 hours following subcutaneous administrations, therapeutic plasma concentrations are likely to be reached within 5-15 minutes after a 1 mg dose in an emergency. Because of the variability in the speed of absorption for IM & SC dosing, and the inability to titrate to effect, great care should be taken if repeated doses must be given by these routes. DISTRIBUTION Following a 1 mg parenteral dose, nalmefene was rapidly distributed. In a study of brain receptor occupancy, a 1 mg dose of nalmefene blocked over 80% of brain opioid receptors within 5 minutes after administration. The apparent volumes of distribution centrally (Vc) and at steady-state (Vdss) are 3.9 ± 1.1 L/kg and 8.6 ± 1.7 L/kg, respectively. Ultrafiltration studies of nalmefene have demonstrated that 45% (CV 4.1%) is bound to plasma proteins over a concentration range of 0.1 to 2 µg/mL. An in vitro determination of the distribution of nalmefene in human blood demonstrated that nalmefene distributed 67% (CV 8.7%) into red blood cells and 39% (CV 6.4%) into plasma. The whole blood to plasma ratio was 1.3 (CV 6.6%) over the nominal concentration range in whole blood from 0.376 to 30 ng/mL. METABOLISM Nalmefene is metabolized by the liver, primarily by glucuronide conjugation, and excreted in the urine. Nalmefene is also metabolized to trace amounts of an N- dealkylated metabolite. Nalmefene glucuronide is inactive and the N-dealkylated metabolite has minimal pharmacological activity. Less than 5% of nalmefene is excreted in the urine unchanged. Seventeen percent (17%) of the nalmefene dose is excreted in the feces. The plasma concentration-time profile in some subjects suggests that nalmefene undergoes enterohepatic recycling. ELIMINATION After intravenous administration of 1 mg nalmefene hydrochloride injection to normal males (ages 19-32), plasma concentrations declined biexponentially with a redistribution and a terminal elimination half-life of 41 ± 34 minutes and 10.8 ± 5.2 hours, respectively. The systemic clearance of nalmefene is 0.8 ± 0.2 L/hr/kg and the renal clearance is 0.08 ± 0.04 L/hr/kg. Special Populations ELDERLY Dose proportionality was observed in nalmefene AUC 0-inf following 0.5 to 2 mg intravenous administration to elderly male subjects. Following a 1 mg intravenous nalmefene dose, there were no significant differences between young (19-32 years) and elderly (62-80 years) adult male subjects with respect to plasma clearance, steady-state volume of distribution, or half-life. There was an apparent age-related decrease in the central volume of distribution (young: 3.9 ± 1.1 L/kg, elderly: 2.8 ± 1.1 L/kg) that resulted in a greater initial nalmefene concentration in the elderly group. While initial nalmefene plasma concentrations were transiently higher in the elderly, it would not be anticipated that this population would require dosing adjustment. No clinical adverse events were noted in the elderly following the 1 mg intravenous nalmefene dose. PATIENTS WITH HEPATIC IMPAIRMENT Subjects with hepatic disease, when compared to matched normal controls, had a 28.3% decrease in plasma clearance of nalmefene (0.56 ± 0.21 L/hr/kg versus 0.78 ± 0.24 L/hr/kg, respectively). Elimination halflife increased from 10.2 ± 2.2 hours to 11.9 ± 2.0 hours in the hepatically impaired. No dosage adjustment is recommended since nalmefene will be administered as an acute course of therapy. PATIENTS WITH RENAL IMPAIRMENT There was a statistically significant 27% decrease in plasma clearance of nalmefene in the end-stage renal disease (ESRD) population during interdialysis (0.57 ± 0.20 L/hr/kg) and a 25% decreased plasma clearance in the ESRD population during intradialysis (0.59 ±0.18 L/hr/kg) compared to normals (0.79 ± 0.24 L/hr/kg). The elimination half-life was prolonged in ESRD patients from 10.2 ± 2.2 hours in normals to 26.1 ± 9.9 hours. (See DOSAGE AND ADMINISTRATION .) GENDER DIFFERENCES There has not been sufficient pharmacokinetic study to make a definitive statement as to whether the pharmacokinetics of nalmefene differs between the genders."],"indications_and_usage":["INDICATIONS AND USAGE Nalmefene Hydrochloride Injection is indicated for the complete or partial reversal of opioid drug effects, including respiratory depression, induced by either natural or synthetic opioids. Nalmefene Hydrochloride Injection is indicated in the management of known or suspected opioid overdose."],"safe_handling_warning":["SAFETY AND HANDLING Nalmefene Hydrochloride Injection is distributed in sealed vials which represent no known risk to health care workers. As with all parenterals, care should be taken to prevent the generation and inhalation of aerosols during preparation and use. Dermal absorption of spilled Nalmefene Hydrochloride Injection should be prevented by prompt removal of contaminated clothing and rinsing the skin thoroughly with cool water. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit."],"pharmacokinetics_table":["
Parameter Young, N=18 Elderly, N=11
Age 19-3262-80
Cp at 5 min. (ng/mL) 3.7 (29)5.8 (38)
Vdss (L/kg) 8.6 (19)8.6 (29)
Vc (L/kg) 3.9 (29)2.8 (41)
AUC0-inf (ng-hr/mL) 16.6 (27)17.3 (14)
Terminal T1/2 (hr) 10.8 (48)9.4 (49)
Clplasma (L/hr/kg) 0.8 (23)0.8 (18)
"],"adverse_reactions_table":["
Adverse Event Nalmefene Naloxone Placebo
N=1127 N=369 N=77
Nausea 18% 18% 6%
Vomiting 9% 7% 4%
Tachycardia 5% 8% -
Hypertension 5% 7% -
Postoperative pain 4% 4% N/A
Fever 3% 4% -
Dizziness 3% 4% 1%
Headache 1% 1% 4%
Chills 1% 1% -
Hypotension 1% 1% -
Vasodilatation 1% 1% -
"],"spl_unclassified_section":["CLINICAL TRIALS Nalmefene hydrochloride injection has been administered to reverse the effects of opioids after general anesthesia and in the treatment of overdose. It has also been used to reverse the systemic effects of intrathecal opioids. Reversal of Postoperative Opioid Depression Nalmefene hydrochloride injection (N=326) was studied in 5 controlled trials in patients who had received morphine or fentanyl intraoperatively. The primary efficacy criterion was the reversal of respiratory depression. A positive reversal was defined as both an increase in respiratory rate by 5 breaths per minute and a minimum respiratory rate of 12 breaths per minute. Five minutes after administration, initial single nalmefene hydrochloride injection doses of 0.1, 0.25, 0.5, or 1.0 µg/kg had effectively reversed respiratory depression in a dose-dependent manner. Twenty minutes after initial administration, respiratory depression had been effectively reversed in most patients receiving cumulative doses within the recommended range (0.1 to 1.0 µg/kg). Total doses of nalmefene hydrochloride injection above 1.0 µg/kg did not increase the therapeutic response. The postoperative administration of nalmefene hydrochloride at the recommended doses did not prevent the analgesic response to subsequently administered opioids. Reversal of the Effect of Intrathecally Administered Opioids Intravenous nalmefene hydrochloride at doses of 0.5 and 1.0 µg/kg was administered to 47 patients given intrathecal morphine. One to 2 doses of 0.5 and 1.0 µg/kg nalmefene hydrochloride reversed respiratory depression in most patients. The administration of nalmefene hydrochloride at the recommended doses did not prevent the analgesic response to subsequently administered opioids. Management of Known or Suspected Opioid Overdose Nalmefene hydrochloride injection (N=284) at doses of 0.5 mg to 2.0 mg was studied in 4 trials of patients who were presumed to have taken an opioid overdose. Nalmefene hydrochloride injection doses of 0.5 mg to 1.0 mg effectively reversed respiratory depression within 2 to 5 minutes in most patients subsequently confirmed to have opioid overdose. A total dose greater than 1.5 mg did not increase the therapeutic response."],"dosage_and_administration":["DOSAGE AND ADMINISTRATION Important Information - Dosage Forms Nalmefene Hydrochloride Injection is supplied in two concentrations that can be identified by their color coded container labels: a concentration suitable for postoperative use (100 µg/mL) in a blue labeled vial containing ONE (1) mL and a concentration suitable for the management of overdose (1 mg/mL, 10 times as concentrated, 20 times as much drug) in a green labeled vial containing TWO (2) mL. Proper steps should be taken to prevent use of the incorrect concentration. General Principles Nalmefene hydrochloride injection should be titrated to reverse the undesired effects of opioids. Once adequate reversal has been established, additional administration is not required and may actually be harmful due to unwanted reversal of analgesia or precipitated withdrawal. Duration of Action The duration of action of nalmefene hydrochloride injection is as long as most opioid analgesics. The apparent duration of action of nalmefene hydrochloride injection will vary, however, depending on the half-life and plasma concentration of the narcotic being reversed, the presence or absence of other drugs affecting the brain or muscles of respiration, and the dose of nalmefene hydrochloride injection administered. Partially reversing doses of nalmefene hydrochloride injection (1 µg/kg) lose their effect as the drug is redistributed through the body, and the effects of these low doses may not last more than 30-60 minutes in the presence of persistent opioid effects. Fully reversing doses (1 mg/70 kg) have been shown to last many hours in both experimental and clinical studies, but may complicate the management of patients who are in pain, at high cardiovascular risk, or who are physically dependent on opioids. The recommended doses represent a compromise between a desirable controlled reversal and the need for prompt response and adequate duration of action. Using higher dosages or shorter intervals between incremental doses is likely to increase the incidence and severity of symptoms related to acute withdrawal such as nausea, vomiting, elevated blood pressure, and anxiety. Patients Tolerant to or Physically Dependent on Opioids Nalmefene hydrochloride injection may cause acute withdrawal symptoms in individuals who have some degree of tolerance to and dependence on opioids. These patients should be closely observed for symptoms of withdrawal following administration of the initial and subsequent injections of nalmefene hydrochloride injection. Subsequent doses should be administered with intervals of at least 2-5 minutes between doses to allow the full effect of each incremental dose of nalmefene hydrochloride injection to be reached. Recommended Doses for Reversal of Postoperative Opioid Depression Use 100 µg/mL dosage strength (blue label) and see Table 2 for initial doses. The goal of treatment with nalmefene hydrochloride injection in the postoperative setting is to achieve reversal of excessive opioid effects without inducing a complete reversal and acute pain. This is best accomplished with an initial dose of 0.25 µg/kg followed by 0.25 µg/kg incremental doses at 2-5 minute intervals, stopping as soon as the desired degree of opioid reversal is obtained. A cumulative total dose above 1.0 µg/kg does not provide additional therapeutic effect. Table 2: Reversal of Postoperative Opioid Depression Body Weight mL of Nalmefene 100 µg/mL Solution 50 kg 0.125 60 kg 0.150 70 kg 0.175 80 kg 0.200 90 kg 0.225 100 kg 0.250 In cases where the patient is known to be at increased cardiovascular risk, it may be desirable to dilute Nalmefene Hydrochloride Injection 1:1 with saline or sterile water and use smaller initial and incremental doses of 0.1 µg/kg. Management of Known or Suspected Opioid Overdose Use 1.0 mg/mL dosage strength (green label). The recommended initial dose of nalmefene hydrochloride injection for non-opioid dependent patients is 0.5 mg/70 kg. If needed, this may be followed by a second dose of 1.0 mg/70 kg, 2-5 minutes later. If a total dose of 1.5 mg /70 kg has been administered without clinical response, additional Nalmefene Hydrochloride Injection is unlikely to have an effect. Patients should not be given more nalmefene hydrochloride injection than is required to restore the respiratory rate to normal, thus minimizing the likelihood of cardiovascular stress and precipitated withdrawal syndrome. If there is a reasonable suspicion of opioid dependency, a challenge dose of nalmefene hydrochloride injection 0.1 mg/70 kg should be administered initially. If there is no evidence of withdrawal in 2 minutes, the recommended dosing should be followed. Nalmefene hydrochloride injection had no effect in cases where opioids were not responsible for sedation and hypoventilation. Therefore, patients should only be treated with Nalmefene Hydrochloride Injection when the likelihood of an opioid overdose is high, based on a history of opioid overdose or the clinical presentation of respiratory depression with concurrent pupillary constriction. Repeated Dosing Nalmefene hydrochloride injection is the longest acting of the currently available parenteral opioid antagonists. If recurrence of respiratory depression does occur, the dose should again be titrated to clinical effect using incremental doses to avoid over-reversal. Hepatic and Renal Disease Hepatic disease and renal failure substantially reduce the clearance of nalmefene (see Pharmacokinetic s ). For single episodes of opioid antagonism, adjustment of nalmefene hydrochloride injection dosage is not required. However, in patients with renal failure, the incremental doses should be delivered slowly (over 60 seconds) to minimize the hypertension and dizziness reported following the abrupt administration of nalmefene to such patients. Loss of Intravenous Access Should intravenous access be lost or not readily obtainable, a pharmacokinetic study has shown that a single dose of nalmefene hydrochloride injection should be effective within 5-15 minutes after intramuscular or subcutaneous doses of 1.0 mg. (see Pharmacokinetics .)"],"drug_abuse_and_dependence":["DRUG ABUSE AND DEPENDENCE Nalmefene hydrochloride injection is an opioid antagonist with no agonist activity. It has no demonstrated abuse potential, is not addictive, and is not a controlled substance."],"spl_product_data_elements":["nalmefene hydrochloride nalmefene hydrochloride injection NALMEFENE HYDROCHLORIDE NALMEFENE SODIUM CHLORIDE HYDROCHLORIC ACID WATER nalmefene hydrochloride nalmefene hydrochloride injection NALMEFENE HYDROCHLORIDE NALMEFENE SODIUM CHLORIDE HYDROCHLORIC ACID WATER"],"clinical_pharmacology_table":["
Parameter Young, N=18 Elderly, N=11
Age 19-3262-80
Cp at 5 min. (ng/mL) 3.7 (29)5.8 (38)
Vdss (L/kg) 8.6 (19)8.6 (29)
Vc (L/kg) 3.9 (29)2.8 (41)
AUC0-inf (ng-hr/mL) 16.6 (27)17.3 (14)
Terminal T1/2 (hr) 10.8 (48)9.4 (49)
Clplasma (L/hr/kg) 0.8 (23)0.8 (18)
"],"use_in_specific_populations":["Special Populations ELDERLY Dose proportionality was observed in nalmefene AUC 0-inf following 0.5 to 2 mg intravenous administration to elderly male subjects. Following a 1 mg intravenous nalmefene dose, there were no significant differences between young (19-32 years) and elderly (62-80 years) adult male subjects with respect to plasma clearance, steady-state volume of distribution, or half-life. There was an apparent age-related decrease in the central volume of distribution (young: 3.9 ± 1.1 L/kg, elderly: 2.8 ± 1.1 L/kg) that resulted in a greater initial nalmefene concentration in the elderly group. While initial nalmefene plasma concentrations were transiently higher in the elderly, it would not be anticipated that this population would require dosing adjustment. No clinical adverse events were noted in the elderly following the 1 mg intravenous nalmefene dose. PATIENTS WITH HEPATIC IMPAIRMENT Subjects with hepatic disease, when compared to matched normal controls, had a 28.3% decrease in plasma clearance of nalmefene (0.56 ± 0.21 L/hr/kg versus 0.78 ± 0.24 L/hr/kg, respectively). Elimination halflife increased from 10.2 ± 2.2 hours to 11.9 ± 2.0 hours in the hepatically impaired. No dosage adjustment is recommended since nalmefene will be administered as an acute course of therapy. PATIENTS WITH RENAL IMPAIRMENT There was a statistically significant 27% decrease in plasma clearance of nalmefene in the end-stage renal disease (ESRD) population during interdialysis (0.57 ± 0.20 L/hr/kg) and a 25% decreased plasma clearance in the ESRD population during intradialysis (0.59 ±0.18 L/hr/kg) compared to normals (0.79 ± 0.24 L/hr/kg). The elimination half-life was prolonged in ESRD patients from 10.2 ± 2.2 hours in normals to 26.1 ± 9.9 hours. (See DOSAGE AND ADMINISTRATION .) GENDER DIFFERENCES There has not been sufficient pharmacokinetic study to make a definitive statement as to whether the pharmacokinetics of nalmefene differs between the genders."],"dosage_and_administration_table":["
Body Weight mL of Nalmefene 100 µg/mL Solution
50 kg 0.125
60 kg 0.150
70 kg 0.175
80 kg 0.200
90 kg 0.225
100 kg 0.250
"],"package_label_principal_display_panel":["Principal Display Panel – 100 mcg/1 mL (100 mcg/mL) Vial Label NDC 82432-101-01 Nalmefene Hydrochloride Injection 100 mcg/1 mL Lot: EXP. Date: Chengdu Shuode Pharmaceutical Co., Ltd Principal Display Panel –2 mg/2 mL (1 mg/mL) Vial Label NDC 82432-102-02 Nalmefene Hydrochloride Injection 2 mg/2 mL (1 mg/mL) Lot: EXP. Date: Chengdu Shuode Pharmaceutical Co., Ltd Principal Display Panel –100 mcg/1 mL (100 mcg/mL) Carton Label Rx only NDC 82432-101-01 Nalmefene Hydrochloride Injection 100 mcg/1 mL For Intravenous/Intramuscular/Subcutaneous use. Discard unused portion. 1 ×1 mL Single-Dose Vial Each mL contains: Nalmefene hydrochloride monohydrate (equivalent to 100 mcg nalmefene base). Sodium Chloride, USP, Hydrochloric Acid, NF, and Water for Injection, USP. Protect from light. Store at 20°C to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Store in original carton. See package insert for dosage and directions for use. This unit package is not to be broken for resale. Manufacturer: Chengdu Shuode Pharmaceutical Co., Ltd No. 9 Lekang Road, Shuangliu District, Chengdu, Sichuan 610200, China (CHN) Principal Display Panel –2 mg/2 mL (1 mg/mL) Carton Label Rx only NDC 82432-102-02 Nalmefene Hydrochloride Injection 2 mg/2 mL (1 mg/mL) For Intravenous/Intramuscular/Subcutaneous use. Discard unused portion. 1 ×2 mL Single-Dose Vial Each mL contains: Nalmefene hydrochloride monohydrate (equivalent to 1 mg nalmefene base). Sodium Chloride, USP, Hydrochloric Acid, NF, and Water for Injection, USP. Protect from light. Store at 20°C to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Store in original carton. See package insert for dosage and directions for use. This unit package is not to be broken for resale. Manufacturer: Chengdu Shuode Pharmaceutical Co., Ltd No. 9 Lekang Road, Shuangliu District, Chengdu, Sichuan 610200, China (CHN) image description image description image description image description"]},"tags":[{"label":"Opioid Antagonist","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Kappa-type opioid receptor","category":"target"},{"label":"OPRK1","category":"gene"},{"label":"OPRM1","category":"gene"},{"label":"OPRD1","category":"gene"},{"label":"N07BB05","category":"atc"},{"label":"Intramuscular","category":"route"},{"label":"Nasal","category":"route"},{"label":"Injection","category":"form"},{"label":"Spray","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Mature","category":"status"},{"label":"Alcoholism","category":"indication"},{"label":"Opiate-Induced Respiratory Depression","category":"indication"},{"label":"Poisoning by opiate analgesic drug","category":"indication"},{"label":"Hikma","category":"company"},{"label":"Approved 1990s","category":"decade"},{"label":"Central Nervous System Agents","category":"pharmacology"},{"label":"Narcotic Antagonists","category":"pharmacology"},{"label":"Peripheral Nervous System Agents","category":"pharmacology"},{"label":"Sensory System Agents","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"llr":229.355,"date":"","count":58,"signal":"Drug withdrawal syndrome","source":"DrugCentral FAERS","actionTaken":"Reported 58 times (LLR=229)"},{"llr":170.074,"date":"","count":56,"signal":"Coma","source":"DrugCentral FAERS","actionTaken":"Reported 56 times (LLR=170)"},{"llr":107.882,"date":"","count":61,"signal":"Drug interaction","source":"DrugCentral FAERS","actionTaken":"Reported 61 times (LLR=108)"},{"llr":87.23,"date":"","count":25,"signal":"Respiratory depression","source":"DrugCentral FAERS","actionTaken":"Reported 25 times (LLR=87)"},{"llr":68.545,"date":"","count":15,"signal":"Bradypnoea","source":"DrugCentral FAERS","actionTaken":"Reported 15 times (LLR=69)"}],"commonSideEffects":[{"effect":"Nausea","drugRate":"18%","severity":"common","_validated":true},{"effect":"Vomiting","drugRate":"9%","severity":"common","_validated":true},{"effect":"Tachycardia","drugRate":"5%","severity":"mild","_validated":true},{"effect":"Hypertension","drugRate":"5%","severity":"mild","_validated":true},{"effect":"Postoperative pain","drugRate":"4%","severity":"mild","_validated":true},{"effect":"Fever","drugRate":"3%","severity":"mild","_validated":true},{"effect":"Dizziness","drugRate":"3%","severity":"mild","_validated":true},{"effect":"Headache","drugRate":"1%","severity":"mild","_validated":true},{"effect":"Hypotension","drugRate":"1%","severity":"mild","_validated":true},{"effect":"Vasodilation","drugRate":"1%","severity":"mild","_validated":true},{"effect":"Chills","drugRate":"reported","severity":"unknown"},{"effect":"Bradycardia","drugRate":"reported","severity":"unknown"},{"effect":"Arrhythmia","drugRate":"reported","severity":"unknown"},{"effect":"Diarrhea","drugRate":"reported","severity":"unknown"},{"effect":"Dry mouth","drugRate":"reported","severity":"unknown"},{"effect":"Somnolence","drugRate":"reported","severity":"unknown"},{"effect":"Depression","drugRate":"reported","severity":"unknown"},{"effect":"Agitation","drugRate":"reported","severity":"unknown"},{"effect":"Nervousness","drugRate":"reported","severity":"unknown"},{"effect":"Tremor","drugRate":"reported","severity":"unknown"},{"effect":"Confusion","drugRate":"reported","severity":"unknown"},{"effect":"Withdrawal syndrome","drugRate":"reported","severity":"unknown"},{"effect":"Myoclonus","drugRate":"reported","severity":"unknown"},{"effect":"Pharyngitis","drugRate":"reported","severity":"unknown"},{"effect":"Pruritus","drugRate":"reported","severity":"unknown"},{"effect":"Urinary retention","drugRate":"reported","severity":"unknown"}],"specialPopulations":{"Pregnancy":"There are no available data on nalmefene use in pregnant women to evaluate for drug-associated risk of major birth defects or miscarriage. In animal reproduction studies, no embryotoxic effects on embryo-fetal development were observed in rats and rabbits treated with nalmefene at exposures at least times (rats) and up to 20 times (rabbits) the exposure at two human nasal doses of 5.4 mg. An opioid overdose is medical emergency and can be fatal for the pregnant woman and fetus if left untreated. Treatment with OPVEE for opioid overdose should not be withheld because of potential concerns regarding the effects of OPVEE on the fetus. There was no evidence of impaired fertility or harm to the fetus. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used with caution in pregnant women.","Geriatric use":"Clinical studies of nalmefene hydrochloride injection did not include sufficient number of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant diseases or other drug therapy.","Paediatric use":"Safety and effectiveness of nalmefene hydrochloride injection in pediatric patients have not been established."}},"trials":[],"aliases":[],"company":"Hikma","patents":[],"pricing":[],"_fixedAt":"2026-03-30T18:28:23.134418","_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=NALMEFENE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:27:43.565375+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Nalmefene","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T03:27:51.314329+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:27:49.529055+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=NALMEFENE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:27:50.018425+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:27:42.462132+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:27:42.462160+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL982/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:27:50.799844+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA216007","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:27:42.462164+00:00"}},"allNames":"revex","offLabel":[],"synonyms":["nalmefene","nalmefene hydrochloride dihydrate","selincro","nalmetrene","6-desoxy-6-methylenenaltrexone","nalmefene hydrochloride","nalmefene HCl","ORF-11676","nalmefene hydrochloride hydrate"],"timeline":[{"date":"1995-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from EUROHLTH INTL SARL to Hikma"},{"date":"1995-04-17","type":"positive","source":"DrugCentral","milestone":"FDA approval (Eurohlth Intl Sarl)"},{"date":"2019-08-01","type":"positive","source":"DrugCentral","milestone":"PMDA approval (Otsuka Pharmaceutical Co., Ltd.)"},{"date":"2022-02-08","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 1 manufacturer approved"},{"date":"2023-05-22","type":"positive","source":"FDA Orange Book","milestone":"Opvee approved — EQ 2.7MG BASE/SPRAY"},{"date":"2024-08-07","type":"positive","source":"FDA Orange Book","milestone":"Zurnai (Autoinjector) approved — EQ 1.5MG BASE/0.5ML (EQ 1.5MG BASE/0.5ML)"}],"aiSummary":"Revex (nalmeftene) is a small molecule opioid antagonist that targets the kappa-type opioid receptor. Originally developed by EUROHLTH INTL SARL, it was approved by the FDA in 1995 for the treatment of alcoholism, opiate-induced respiratory depression, and poisoning by opiate analgesic drugs. As an off-patent medication, Revex is available as a generic product from multiple manufacturers. Key safety considerations include its half-life of 8.8 hours and bioavailability of 40%. Revex is a commercial product with a stable market presence.","approvals":[{"date":"1995-04-17","orphan":false,"company":"EUROHLTH INTL SARL","regulator":"FDA"},{"date":"2019-08-01","orphan":false,"company":"OTSUKA PHARMACEUTICAL CO., LTD.","regulator":"PMDA"}],"brandName":"Revex","ecosystem":[{"indication":"Alcoholism","otherDrugs":[{"name":"acamprosate","slug":"acamprosate","company":"Forest Labs"},{"name":"disulfiram","slug":"disulfiram","company":""},{"name":"naltrexone","slug":"naltrexone","company":"Teva Womens"}],"globalPrevalence":null},{"indication":"Opiate-Induced Respiratory Depression","otherDrugs":[{"name":"naloxone","slug":"naloxone","company":"Adapt"}],"globalPrevalence":null},{"indication":"Poisoning by opiate analgesic drug","otherDrugs":[{"name":"naloxone","slug":"naloxone","company":"Adapt"}],"globalPrevalence":null}],"mechanism":{"target":"Kappa-type opioid receptor","novelty":"Follow-on","targets":[{"gene":"OPRK1","source":"DrugCentral","target":"Kappa-type opioid receptor","protein":"Kappa-type opioid receptor","isPrimary":true,"activityType":"Ki","activityValue":9.92},{"gene":"OPRM1","source":"DrugCentral","target":"Mu-type opioid receptor","protein":"Mu-type opioid receptor"},{"gene":"OPRD1","source":"DrugCentral","target":"Delta-type opioid receptor","protein":"Delta-type opioid receptor"}],"moaClass":"Opioid Antagonists","modality":"Small Molecule","drugClass":"Opioid Antagonist","explanation":"","oneSentence":"","technicalDetail":"Revex (nalmeftene) is a selective kappa opioid receptor antagonist that acts as a competitive inhibitor, binding to the receptor and preventing the endogenous ligand from interacting with it, thereby reducing the reinforcing effects of opioids and alcohol."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Nalmefene","title":"Nalmefene","extract":"Nalmefene, sold under the brand name Revex among others, is a medication that is used in the treatment of opioid overdose and alcohol dependence. Nalmefene belongs to the class of opioid antagonists and can be taken by mouth, administered by injection, or delivered through nasal administration.","wiki_society_and_culture":"==Society and culture==\nNalmefene was first reported in a patent in 1974.\n\n=== Legal status ===\n==== United States ====\nIn the United States, immediate-release injectable nalmefene was approved in 1995, as an antidote for opioid overdose. It was sold under the brand name Revex. A generic version was approved for medical use in the United States in February 2022.\n\nIn May 2023, the Food and Drug Administration (FDA) approved a nalmefene hydrochloride nasal spray, under the brand name Opvee, for the emergency treatment of opioid overdose in people aged twelve years of age and older. The FDA granted the application for the nalmefene hydrochloride auto-injector fast track and priority review designations. In 2011, they submitted an application for their medication named Selincro to the European Medicines Agency. The medication was authorized for use in the EU in March 2013. and in October 2013, Scotland became the first country in the EU to prescribe the drug for alcohol dependence. England followed Scotland by offering the medication as a treatment for problem drinking in October 2014. In November 2014, nalmefene was approved as a possible treatment supplied by Britain's National Health Service (NHS) for reducing alcohol consumption in people with alcohol dependence."},"commercial":{"launchDate":"1995","revenueYear":2024,"_launchSource":"DrugCentral (FDA 1995-04-17, EUROHLTH INTL SARL)","annualRevenue":400,"revenueSource":"Verified: Alkermes 10-K","revenueCurrency":"USD","revenueConfidence":"verified"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1876","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=NALMEFENE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=NALMEFENE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Nalmefene","fields":["history","overview"],"source":"Wikipedia"},{"id":5,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T15:04:31.259537","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:27:53.750124+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"disulfiram","drugSlug":"disulfiram","fdaApproval":"1951-08-28","genericCount":9,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"acamprosate","drugSlug":"acamprosate","fdaApproval":"2004-07-29","genericCount":5,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"naltrexone","drugSlug":"naltrexone","fdaApproval":"1984-11-20","patentExpiry":"Oct 15, 2029","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"nalmefene","indications":{"approved":[{"name":"Alcoholism","source":"DrugCentral","snomedId":7200002,"regulator":"FDA","eligibility":"no specific eligibility criteria mentioned"},{"name":"Opiate-Induced Respiratory Depression","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"no specific eligibility criteria mentioned"},{"name":"Poisoning by opiate analgesic drug","source":"DrugCentral","snomedId":241749009,"regulator":"FDA","eligibility":"no specific eligibility criteria mentioned"}],"offLabel":[],"pipeline":[]},"_fixedFields":["primaryTarget"],"currentOwner":"Hikma","drugCategory":"mature","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"disulfiram","brandName":"disulfiram","genericName":"disulfiram","approvalYear":"1951","relationship":"same-class"},{"drugId":"acamprosate","brandName":"acamprosate","genericName":"acamprosate","approvalYear":"2004","relationship":"same-class"},{"drugId":"naltrexone","brandName":"naltrexone","genericName":"naltrexone","approvalYear":"1984","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT04713358","phase":"PHASE4","title":"Effect of Nalmefene on the Quality of Resuscitation in Patients Under General Anesthesia","status":"COMPLETED","sponsor":"RenJi Hospital","startDate":"2021-09-24","conditions":["Resuscitation"],"enrollment":542,"completionDate":"2023-12-31"},{"nctId":"NCT07325279","phase":"PHASE1","title":"Nalmefene Implant in Healthy Subjects","status":"NOT_YET_RECRUITING","sponsor":"ReacX Pharmaceuticals, Inc.","startDate":"2026-01-07","conditions":["Opioid Abuse and Addiction"],"enrollment":24,"completionDate":"2026-12-01"},{"nctId":"NCT02639273","phase":"PHASE1","title":"Title: Effect of Opioid Receptor Modulation on Alcohol Self-Administration and Neural Response to Alcohol Cues in Heavy Drinkers: Role of OPRM1 Gene Variation","status":"COMPLETED","sponsor":"National Institute on Alcohol Abuse and Alcoholism (NIAAA)","startDate":"2016-06-08","conditions":["AUD"],"enrollment":13,"completionDate":"2023-12-08"},{"nctId":"NCT06733519","phase":"PHASE2","title":"TH104 for the Treatment of Pruritus in Primary Biliary Cholangitis","status":"NOT_YET_RECRUITING","sponsor":"Tharimmune Inc","startDate":"2026-06-01","conditions":["Pruritus","Primary Biliary Cholangitis"],"enrollment":40,"completionDate":"2027-06-01"},{"nctId":"NCT04828005","phase":"PHASE1","title":"Pharmacodynamic Evaluation of Intranasal Nalmefene","status":"COMPLETED","sponsor":"Opiant Pharmaceuticals Inc","startDate":"2021-03-30","conditions":["Pharmacodynamic"],"enrollment":84,"completionDate":"2022-03-14"},{"nctId":"NCT06719986","phase":"PHASE1","title":"Pharmacodynamic Evaluation of Intramuscular Nalmefene Autoinjector 1.5 mg Compared to Intranasal Narcan 4 mg","status":"COMPLETED","sponsor":"Purdue Pharma LP","startDate":"2022-10-03","conditions":["Opioid Overdose"],"enrollment":24,"completionDate":"2022-12-23"},{"nctId":"NCT06198686","phase":"PHASE1","title":"An Evaluation of The Absolute Bioavailability of TH104","status":"COMPLETED","sponsor":"Tharimmune Inc","startDate":"2024-01-26","conditions":["Healthy"],"enrollment":20,"completionDate":"2024-11-06"},{"nctId":"NCT04107051","phase":"","title":"Post-Marketing Surveillance Study of Nalmefene Hydrochloride Hydrate in Patients with Alcohol Dependence","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2019-10-01","conditions":["Alcohol Dependence"],"enrollment":533,"completionDate":"2024-02-06"},{"nctId":"NCT05540288","phase":"PHASE3","title":"NAlmefene Versus Placebo in Addition to Treatment as Usual on Craving in Behavioural Addictions","status":"RECRUITING","sponsor":"Nantes University Hospital","startDate":"2023-03-31","conditions":["Behavioural Addiction"],"enrollment":266,"completionDate":"2027-07"},{"nctId":"NCT06408714","phase":"PHASE3","title":"Nalmefene vs Naloxone for the Treatment of Recurrent Respiratory Depression After Opioid Overdose","status":"WITHDRAWN","sponsor":"University of New Mexico","startDate":"2024-08-26","conditions":["Opioid Overdose","Opiate Overdose"],"enrollment":0,"completionDate":"2024-12-09"},{"nctId":"NCT05338632","phase":"PHASE1","title":"Reversal of Opioid-induced Respiratory Depression With Opioid Antagonists","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2022-06-24","conditions":["Opioid Induced Respiratory Depression","Chronic Opioid Use"],"enrollment":24,"completionDate":"2026-10-01"},{"nctId":"NCT04759768","phase":"PHASE1","title":"Pharmacokinetic Evaluation of Intranasal Nalmefene","status":"COMPLETED","sponsor":"Opiant Pharmaceuticals Inc","startDate":"2021-02-08","conditions":["Pharmacokinetics"],"enrollment":68,"completionDate":"2021-05-24"},{"nctId":"NCT05219669","phase":"PHASE1","title":"Pharmacokinetic Evaluation of Intranasal Nalmefene Using Three Dosing Regimens","status":"COMPLETED","sponsor":"Opiant Pharmaceuticals Inc","startDate":"2021-09-01","conditions":["Opioid Overdose"],"enrollment":24,"completionDate":"2021-11-22"},{"nctId":"NCT02824354","phase":"PHASE3","title":"Nalmefene in Patients With Alcoholic Compensated Cirrhosis for the Treatment of Alcohol Dependence.","status":"WITHDRAWN","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2018-12-01","conditions":["Cirrhosis","Alcohol Dependence","Nalmefene"],"enrollment":0,"completionDate":"2022-12-01"},{"nctId":"NCT05808881","phase":"PHASE4","title":"Clinical Outcomes From Nalmefene","status":"WITHDRAWN","sponsor":"Purdue Pharma LP","startDate":"2023-06","conditions":["Opioid Overdose"],"enrollment":0,"completionDate":"2024-05"},{"nctId":"NCT03096730","phase":"NA","title":"Effect of Dexmedetomidine Combined With Low-dose Nalmefene on Preventing Remifentanil-induced Postoperative Hyperalgesia","status":"COMPLETED","sponsor":"Tianjin Medical University General Hospital","startDate":"2017-02-06","conditions":["Pain","Anesthesia"],"enrollment":150,"completionDate":"2017-12-30"},{"nctId":"NCT03279562","phase":"PHASE1","title":"Patient Driven Recovery With Nalmefene and Coaching","status":"COMPLETED","sponsor":"Yale University","startDate":"2017-09-01","conditions":["Opioid-use Disorder","Harmful; Use, Alcohol"],"enrollment":10,"completionDate":"2019-12-30"},{"nctId":"NCT03034408","phase":"PHASE2","title":"Nalmefene, Baclofen and Impulsivity in Subjects With Alcohol Use Disorder and Healthy Control Subjects","status":"COMPLETED","sponsor":"Prof. Daniele Zullino","startDate":"2016-07-01","conditions":["Alcohol Use Disorder"],"enrollment":37,"completionDate":"2018-12-17"},{"nctId":"NCT03278886","phase":"PHASE1,PHASE2","title":"St. PETERsburg Pain and Alcohol Intervention With Naltrexone and Nalmefene","status":"COMPLETED","sponsor":"Boston Medical Center","startDate":"2018-07-03","conditions":["HIV Infection","Alcohol Use","Pain"],"enrollment":11,"completionDate":"2018-12-19"},{"nctId":"NCT02382276","phase":"PHASE3","title":"A Long-term Extension Study for the Phase 3 Study of Nalmefene (339-14-001) in Patients With Alcohol Dependence","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2015-07-13","conditions":["Alcohol Dependence"],"enrollment":405,"completionDate":"2017-01-18"},{"nctId":"NCT02364947","phase":"PHASE3","title":"A Multicenter, Randomized, Double-blind, Placebo-controlled, 3-parallel-group Comparison Trial to Investigate the Effect of Nalmefene on Alcohol Consumption Reduction in Patients With Alcohol Dependence (Phase 3 Trial)","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2015-02-09","conditions":["Alcohol Dependence"],"enrollment":678,"completionDate":"2016-07-30"},{"nctId":"NCT02492581","phase":"","title":"Use of Selincro and Impact on Usual Practice","status":"COMPLETED","sponsor":"University of Bordeaux","startDate":"2016-02","conditions":["Alcohol Dependence"],"enrollment":700,"completionDate":"2018-04"},{"nctId":"NCT03129347","phase":"PHASE1","title":"Pharmacokinetic Evaluation of Nalmefene Administered Intranasally to Healthy Volunteers","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2017-06-01","conditions":["Opioid-Related Disorders"],"enrollment":14,"completionDate":"2017-07-03"},{"nctId":"NCT02372318","phase":"EARLY_PHASE1","title":"Single-dose of Nalmefene to Modulate Neural Alcohol Cue Reactivity","status":"TERMINATED","sponsor":"Central Institute of Mental Health, Mannheim","startDate":"2015-04","conditions":["Alcoholism"],"enrollment":23,"completionDate":"2016-05"},{"nctId":"NCT00000450","phase":"PHASE4","title":"Naltrexone Maintenance Treatment of Alcoholism","status":"COMPLETED","sponsor":"The Scripps Research Institute","startDate":"1997-04-10","conditions":["Alcoholism"],"enrollment":159,"completionDate":"2002-02-13"},{"nctId":"NCT00000437","phase":"PHASE4","title":"Tobacco Dependence in Alcoholism Treatment (Nicotine Patch/Naltrexone)","status":"COMPLETED","sponsor":"The Scripps Research Institute","startDate":"1997-09-26","conditions":["Alcoholism","Smoking"],"enrollment":60,"completionDate":"2005-09-15"},{"nctId":"NCT02679469","phase":"PHASE1","title":"A Single-center, Open-label, Single-dose Study Investigating the Safety, Tolerability, and Pharmacokinetic Properties of Nalmefene 10 mg Tablets in Healthy Japanese Male Subjects","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2016-02","conditions":["Alcohol Dependence"],"enrollment":7,"completionDate":"2016-03"},{"nctId":"NCT02195817","phase":"PHASE4","title":"Study of 18 mg Selincro® As-needed Use, in the Treatment of Patients With Alcohol Dependence in Primary Care","status":"TERMINATED","sponsor":"H. Lundbeck A/S","startDate":"2014-08","conditions":["Alcohol Dependence"],"enrollment":378,"completionDate":"2016-02"},{"nctId":"NCT02197598","phase":"PHASE4","title":"Treatment of Patients Suffering of Alcohol Dependence and Impaired Liver Function With Selincro® As-needed Use","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2014-09","conditions":["Alcohol Dependence"],"enrollment":45,"completionDate":""},{"nctId":"NCT01934166","phase":"PHASE1","title":"Pharmacokinetic Properties of Nalmefene in Subjects With Renal Impairment and in Healthy Subjects","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2013-07","conditions":["Renal Impairment"],"enrollment":32,"completionDate":""},{"nctId":"NCT02934919","phase":"PHASE2","title":"Evaluation of Nalmefene in Impulse Control Disorders in Parkinson's Disease: A Prospective Open Label Study","status":"UNKNOWN","sponsor":"University Hospital, Clermont-Ferrand","startDate":"2016-12","conditions":["Impulse Control Disorders","Parkinson Disease"],"enrollment":30,"completionDate":"2018-05"},{"nctId":"NCT02752503","phase":"NA","title":"Nalmefene in Alcohol Dependence and Borderline Personality Disorder","status":"UNKNOWN","sponsor":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","startDate":"2015-03","conditions":["Alcohol Use Disorder","Borderline Personality Disorder"],"enrollment":30,"completionDate":""},{"nctId":"NCT01969617","phase":"PHASE1","title":"Effects of Nalmefene After Single Dose on the Blood Oxygen Level Dependent (BOLD) fMRI Signal in the Ventral Striatum to Reward Responding in the Monetary Incentive Delay Task (MIDT), in Non-treatment Seeking Subjects With Alcohol Dependence Following Alcohol Challenge","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2013-11","conditions":["Alcohol Dependence"],"enrollment":22,"completionDate":""},{"nctId":"NCT00811941","phase":"PHASE3","title":"Safety and Efficacy of Nalmefene in Patients With Alcohol Dependence","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2009-03","conditions":["Alcohol Dependence"],"enrollment":665,"completionDate":"2010-11"},{"nctId":"NCT00812461","phase":"PHASE3","title":"Efficacy of Nalmefene in Patients With Alcohol Dependence","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2009-03","conditions":["Alcohol Dependence"],"enrollment":678,"completionDate":"2011-04"},{"nctId":"NCT00811720","phase":"PHASE3","title":"Efficacy of Nalmefene in Patients With Alcohol Dependence","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2008-12","conditions":["Alcohol Dependence"],"enrollment":598,"completionDate":"2010-11"},{"nctId":"NCT00202696","phase":"PHASE2","title":"Nalmefene Smoking Cessation Study","status":"COMPLETED","sponsor":"Somaxon Pharmaceuticals","startDate":"2005-09","conditions":["Smoking Cessation"],"enrollment":76,"completionDate":"2006-03"},{"nctId":"NCT00132119","phase":"PHASE2,PHASE3","title":"Nalmefene Gambling Study: Study of Nalmefene HCl in the Treatment of Pathological Gambling","status":"COMPLETED","sponsor":"Somaxon Pharmaceuticals","startDate":"2005-08","conditions":["Pathological Gambling"],"enrollment":233,"completionDate":"2006-08"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Intramuscular","formulation":"Injection, Spray","formulations":[{"form":"INJECTION, SOLUTION","route":"INTRAMUSCULAR","productName":"NALMEFENE HYDROCHLORIDE"},{"form":"SPRAY","route":"NASAL","productName":"OPVEE"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000022000","MMSL":"357929","NDDF":"005023","UNII":"TOV02TDP9I","VUID":"4023995","CHEBI":"CHEBI:7457","VANDF":"4020923","INN_ID":"5189","RXNORM":"236069","UMLSCUI":"C0068377","chemblId":"CHEMBL982","ChEMBL_ID":"CHEMBL982","KEGG_DRUG":"D05111","DRUGBANK_ID":"DB06230","PUBCHEM_CID":"5284594","SNOMEDCT_US":"109098006","IUPHAR_LIGAND_ID":"1628","SECONDARY_CAS_RN":"1228646-70-5","MESH_SUPPLEMENTAL_RECORD_UI":"C038981"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"1995-","companyName":"Eurohlth Intl Sarl","relationship":"Original Developer"},{"period":"present","companyName":"Hikma","relationship":"Current Owner"},{"period":"2019","companyName":"Otsuka Pharmaceutical Co., Ltd.","relationship":"PMDA Licensee"}],"pharmacokinetics":{"source":"DrugCentral","halfLife":"8.8 hours","clearance":"15.0 mL/min/kg","bioavailability":"40%","fractionUnbound":"0.65%","volumeOfDistribution":"8.2 L/kg"},"publicationCount":551,"therapeuticAreas":["Neuroscience"],"_revenueScrapedAt":"2026-04-08 13:58:51.840478+00","atcClassification":{"source":"DrugCentral","atcCode":"N07BB05","allCodes":["N07BB05"]},"biosimilarFilings":[],"originalDeveloper":"Eurohlth Intl Sarl","recentPublications":[],"companionDiagnostics":[],"genericManufacturers":2,"_genericFilersChecked":true,"genericManufacturerList":["Chengdu Shuode","Purdue Pharma Lp"],"status":"approved","companyName":"Hikma","companyId":"hikma","modality":"Small molecule","firstApprovalDate":"1995","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1995-04-17T00:00:00.000Z","mah":"EUROHLTH INTL SARL","brand_name_local":null,"application_number":""},{"country_code":"JP","regulator":"PMDA","status":"approved","approval_date":"2019-08-01T00:00:00.000Z","mah":"OTSUKA PHARMACEUTICAL CO., LTD.","brand_name_local":null,"application_number":""},{"country_code":"BG","regulator":"BDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Selincro","application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"AU","regulator":"TGA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Selincro","application_number":null},{"country_code":"CH","regulator":"Swissmedic","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Selincro","application_number":null},{"country_code":"NO","regulator":"NoMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Selincro","application_number":null},{"country_code":"IS","regulator":"IMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Selincro","application_number":null},{"country_code":"NZ","regulator":"Medsafe","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Selincro","application_number":null},{"country_code":"AT","regulator":"AGES","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Selincro","application_number":null},{"country_code":"BE","regulator":"FAMHP","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Selincro","application_number":null},{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Selincro","application_number":"EMEA/H/C/002583"},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Selincro","application_number":null},{"country_code":"HR","regulator":"HALMED","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Selincro","application_number":null},{"country_code":"CY","regulator":"PHS","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Selincro","application_number":null},{"country_code":"CZ","regulator":"SUKL","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Selincro","application_number":null},{"country_code":"DK","regulator":"DKMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Selincro","application_number":null},{"country_code":"EE","regulator":"SAM","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Selincro","application_number":null},{"country_code":"FI","regulator":"Fimea","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Selincro","application_number":null},{"country_code":"FR","regulator":"ANSM","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Selincro","application_number":null},{"country_code":"DE","regulator":"BfArM","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Selincro","application_number":null},{"country_code":"GR","regulator":"EOF","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Selincro","application_number":null},{"country_code":"HU","regulator":"OGYEI","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Selincro","application_number":null},{"country_code":"IE","regulator":"HPRA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Selincro","application_number":null},{"country_code":"IT","regulator":"AIFA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Selincro","application_number":null},{"country_code":"LV","regulator":"ZVA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Selincro","application_number":null},{"country_code":"LT","regulator":"VVKT","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Selincro","application_number":null},{"country_code":"LU","regulator":"MS","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Selincro","application_number":null},{"country_code":"MT","regulator":"MMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Selincro","application_number":null},{"country_code":"NL","regulator":"MEB","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Selincro","application_number":null},{"country_code":"PL","regulator":"URPL","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Selincro","application_number":null},{"country_code":"PT","regulator":"Infarmed","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Selincro","application_number":null},{"country_code":"RO","regulator":"ANMDMR","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Selincro","application_number":null},{"country_code":"SK","regulator":"SIDC","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Selincro","application_number":null},{"country_code":"SI","regulator":"JAZMP","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Selincro","application_number":null},{"country_code":"ES","regulator":"AEMPS","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Selincro","application_number":null},{"country_code":"SE","regulator":"MPA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Selincro","application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":3,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:27:53.750124+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}